Bone growth promoter promises better health in achondroplasia

A biologic analogue of C-type natriuretic peptide is showing promise as a therapy to improve bone growth in children with achondroplasia. An international phase 2 dose-finding and extension study, led by Melbourne clinical geneticist Professor Ravi Savarirayan, has found daily subcutaneous injections of vosoritide were well tolerated in the children. The study of 35 children ...

Already a member?

Login to keep reading.

© 2021 the limbic